Science-led biopharmaceutical company AstraZeneca (LSE: AZN) announced on Tuesday that it is strengthening its presence in cell therapy with a USD300m investment in a new facility in Rockville, Maryland.
The state-of-the-art site will focus on manufacturing T-cell therapies for critical cancer trials, creating over 150 skilled jobs. Proximity to AstraZeneca's R&D centres and the thriving life sciences corridor in Maryland supports talent recruitment. The facility joins AstraZeneca's global network and complements its US manufacturing sites, contributing to the production of small molecules and biologics.
AstraZeneca aims to empower T-cells for enhanced cancer treatment. The company's cell therapy portfolio includes armoured autologous CAR-Ts, like Glypican 3 (GPC3) targeting CAR-Ts in hepatocellular carcinoma. Ongoing developments include AZD5851 in Phase I globally and AZD7003 / C-CAR031 co-developed with AbelZeta in China. The pipeline also features early-stage candidates AZD6422 and AZD0754, targeting solid tumors. Additionally, AstraZeneca advances T-cell receptor therapies (TCR-Ts) through its subsidiary Neogene Therapeutics.
AstraZeneca's commitment to innovative medicine spans Oncology, Rare Diseases, BioPharmaceuticals, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. Operating globally, the company focuses on discovery, development and commercialisation to benefit millions of patients worldwide.
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Royalty Pharma acquires RYTELO royalty interest from Geron
Minghui Pharmaceutical announces initial MHB039A Phase I clinical trial results
REGENXBIO reports reduced net loss for nine months to September 2024
Sanofi's Dupixent approved for young children with eosinophilic esophagitis
Research Grid raises USD6.5m seed round
Duoning Biotechnology partners with Branca Bunus on transfection reagents
Intra-Cellular Therapies' CAPLYTA shows promise in preventing schizophrenia relapse
FDA accepts Ionis Pharmaceuticals' donidalorsen New Drug Application
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis